Abstract
This study was conducted to evaluate the epidemiology and clinical features of bloodstream infections caused by extended-spectrum β-lactamase-producing E. coli (ESBL-EC) in community-onset bacteremia. Of 929 episodes of community-onset E. coli bacteremia, 4.1% (38/929) had bacteremia with ESBL producers. Of these, 63.2% (24/38) were further classified as healthcare-associated infections. Although most patients had risk factors for infection due to ESBL producers, three patients with urinary tract infection, four patients with cholangitis, and one patient with a liver abscess had no identified predisposing risk factors. The 30-day mortality was 21.1% (8/38). ESBL-EC is a significant cause of bloodstream infection, even in patients with community-onset infection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bush K (2001) New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32:1085–1089
Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686
Rodriguez-Bano J, Navarro MD, Romero L et al (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43:1407–1414
Rodriguez-Bano J, Navarro MD, Romero L et al (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089–1094
Colodner R, Rock W, Chazan B et al (2004) Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23:163–167
Kang CI, Kim SH, Park WB et al (2004) Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581
Friedman ND, Kaye KS, Stout JE et al (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definitions of community-acquired bacteremia. Ann Intern Med 137:791–797
Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G (2003) Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis 9:1024–1025
Chambers HF (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 8:178–182
Tomasz A (1999) New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med 107:55S–62S
Pedersen G, Schonheyder HC, Steffensen FH, Sorensen HT (1999) Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother 43:119–126
Paterson DL, Ko WC, Von Gottberg A et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212
Author information
Authors and Affiliations
Corresponding author
Additional information
C.I. Kang and H.S. Cheong contributed equally to the study.
Rights and permissions
About this article
Cite this article
Kang, CI., Cheong, H.S., Chung, D.R. et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli . Eur J Clin Microbiol Infect Dis 27, 85–88 (2008). https://doi.org/10.1007/s10096-007-0401-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-007-0401-6